Clinical Trials Logo

Filter by:
NCT ID: NCT04756323 Active, not recruiting - COVID-19 Clinical Trials

A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

Start date: October 27, 2020
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.

NCT ID: NCT04754139 Active, not recruiting - Clinical trials for HIV Preexposure Prophylaxis

A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population

Start date: September 24, 2021
Phase: N/A
Study type: Interventional

This study aims to use a social media mini-application-enabled intervention to successfully promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk people 18 years and above (including men who have sex with men (MSM), transgender women, sex workers, and other key populations) in Wuhan and Guangzhou, China.

NCT ID: NCT04752332 Active, not recruiting - Breast Neoplasms Clinical Trials

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

eMonarcHER
Start date: May 10, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.

NCT ID: NCT04750382 Active, not recruiting - Clinical trials for Triple-negative Breast Cancer

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

Start date: July 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.

NCT ID: NCT04749485 Active, not recruiting - Melanoma Clinical Trials

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Start date: November 8, 2018
Phase: Phase 2
Study type: Interventional

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated.

NCT ID: NCT04747496 Active, not recruiting - Clinical trials for Non-valvular Atrial Fibrillation

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

ETNA-AF-CHINA
Start date: February 26, 2021
Phase:
Study type: Observational

The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.

NCT ID: NCT04743726 Active, not recruiting - Clinical trials for Endoscopy, Gastrointestinal

Research on the Physiological Characteristics of the Gastrointestinal Tract in Chinese Volunteers

Start date: October 31, 2020
Phase:
Study type: Observational [Patient Registry]

The dissolution and absorption of oral drugs in the gastrointestinal tract is a complex process, which is affected by physiological factors such as transporters, metabolic enzymes, gene phenotypes, gastrointestinal diseases, intestinal flora and so on. Therefore, the investigators are planning to collect gastrointestinal mucosa tissues, gastric juice, saliva , feces and blood samples to investigate (1) the activity and abundance of metabolism enzymes/transports in different section of gastrointestinal tract, (2) the composition and physicochemical properties of gastric juice; (3) the distribution and abundance of bacterial in gastrointestinal mucosa, saliva, gastric juice and feces; (4) the composition and content of bile acid in gastrointestinal mucosa, gastric juice and plasma in Chinese volunteers who planning to undergo digestive endoscopy.

NCT ID: NCT04741295 Active, not recruiting - Adenomyosis Clinical Trials

Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

In assisted reproductive technology, adenomyosis patients are characterized by lower clinical pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study is to explore whether low molecular weight heparin can reduce the abortion rate of adenomyosis patients in frozen thawed embryo transfer cycles.

NCT ID: NCT04740918 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

KATE3
Start date: June 7, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or MBC.Participants must have progressed either during or after prior trastuzumab- (+/- pertuzumab) and taxane-based therapy for LABC/MBC; or during (or within 6 months after completing) trastuzumab- (+/-pertuzumab) and taxane-based therapy in the neoadjuvant and/or adjuvant setting.

NCT ID: NCT04740671 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.